Semaglutide should be a part of a broader weight management plan that includes other lifestyle changes like diet and exercise
Among Americans who have never taken GLP-1s but are considering beginning treatment in the next 12 months, 25.1% cite the pill option as the primary factor influencing their desire to begin treatment, and among the 9.3% of Americans who have discontinued GLP-1 treatments, 44.1% say they are considering resuming treatments because of pill options
However, some patients may be advised to withhold Rybelsus temporarily, particularly if they: Are experiencing significant gastrointestinal side effects Are in the dose-escalation phase of treatment Have known gastroparesis or delayed gastric emptying Are undergoing procedures with higher aspiration risk If your clinical team does recommend withholding Rybelsus, they will provide specific instructions about when to stop
Not every patient who asks for CJC-1295/Ipamorelin is a candidate, and candid screening is part of what intake is for
A tapering schedule under medical supervision is recommended for safely discontinuing use